Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Soligenix Inc (NASDAQ:SNGX)

2.22
Delayed Data
As of Nov 17
 0.00 / 0.00%
Today’s Change
1.74
Today|||52-Week Range
5.08
-1.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$19.4M

Company Description

Soligenix, Inc. is a clinical stage biopharmaceutical company, which engages in developing products to treat serious gastrointestinal diseases. It operates through the BioTherapeutics and Vaccines or BioDefense segments. The BioTherapeutics segment involves in the development of photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. The Vaccines or BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.

Contact Information

Soligenix, Inc.
29 Emmons Drive
Princeton New Jersey 08540-5919
P:(609) 538-8200
Investor Relations:

Employees

Shareholders

Individual stakeholders7.36%
Other institutional16.89%
Mutual fund holders0.92%

Top Executives

Christopher J. SchaberChairman, President & Chief Executive Officer
Karen R. KrumeichChief Financial Officer, Secretary & Senior VP
Oreola DoniniChief Scientific Officer & Senior Vice President
Richard C. StraubeChief Medical Officer & Senior Vice President
Adam T. RumageVP-Regulatory Affairs & Project Management